ArticleBMJ open2014
Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997-2010.
Article in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Increasing postgraduate medical mycology research dissertations at Uganda's higher institution of learning.IJID regions · 2025Article
- Social Mycology: Using Social Media Networks in the Management of Aspergillosis and Other Mycoses.Mycopathologia · 2023Review
- Development, preparation, and evaluation of a novel dotted lateral flow immunochromatographic kit for rapid diagnosis of dermatophytosis.Scientific reports · 2023Article
- An update on the development of novel antifungal agents for eumycetoma.Frontiers in pharmacology · 2023Review
- Environmental factors and stochasticity affect the fungal community structures in the water and sediments of Hulun Lake, China.Ecology and evolution · 2022Article
- Genetic validation of Aspergillus fumigatus phosphoglucomutase as a viable therapeutic target in invasive aspergillosis.The Journal of biological chemistry · 2022Article
- Biosensors and Diagnostics for Fungal Detection.Journal of fungi (Basel, Switzerland) · 2020Review
- Cross-Disciplinary Genomics Approaches to Studying Emerging Fungal Infections.Life (Basel, Switzerland) · 2020Review
- Targeting a critical step in fungal hexosamine biosynthesis.The Journal of biological chemistry · 2020Article
- Searching for a change: The need for increased support for public health and research on fungal diseases.PLoS neglected tropical diseases · 2018Article
- Diagnosing Emerging Fungal Threats: A One Health Perspective.Frontiers in genetics · 2018Article
- Predicting Invasive Aspergillosis in Hematology Patients by Combining Clinical and Genetic Risk Factors with Early Diagnostic Biomarkers.Journal of clinical microbiology · 2018Article
- Tackling emerging fungal threats to animal health, food security and ecosystem resilience.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2016Article
- Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013.EBioMedicine · 2016Article
- Noisy neighbourhoods: quorum sensing in fungal-polymicrobial infections.Cellular microbiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesFungal infections cause significant global morbidity and mortality. We have previously described the UK investments in global infectious disease research, and here our objective is to describe the investments awarded to UK institutions for mycology research and outline potential funding gaps in the UK portfolio.
designSystematic analysis.
settingUK institutions carrying out infectious disease research. PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcome is the amount of funding and number of studies related to mycology research. Secondary outcomes are describing the investments made to specific fungal pathogens and diseases, and also the type of science along the R&D value chain.
methodsWe systematically searched databases and websites for information on research studies from public and philanthropic funding institutions awarded between 1997 and 2010, and highlighted the mycology-related projects.
resultsOf 6165 funded studies, we identified 171 studies related to mycology (total investment £48.4 million, 1.9% of all infection research, with mean annual funding £3.5 million). Studies related to global health represented 5.1% of this funding (£2.4 million, compared with 35.6% of all infectious diseases). Leading funders were the Biotechnology and Biological Sciences Research Council (£14.8 million, 30.5%) and Wellcome Trust (£12.0 million, 24.7%). Preclinical studies received £42.2 million (87.3%), with clinical trials, intervention studies and implementation research in total receiving £6.2 million (12.7%). By institution, University of Aberdeen received most funding (£16.9 million, 35%). Studies investigating antifungal resistance received £1.5 million (3.2%).
conclusionsThere is little translation of preclinical research into clinical trials or implementation research in spite of substantial disease burden globally, and there are few UK institutions that carry out significant quantities of mycology research of any type. In the context of global health and the burden of disease in low-income countries, more investment is required for mycology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.